Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $442.6 million.

  • IDEAYA Biosciences' Non-Current Assets rose 189.21% to $442.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 2541.02%. This contributed to the annual value of $442.6 million for FY2025, which is 189.21% up from last year.
  • IDEAYA Biosciences' Non-Current Assets amounted to $442.6 million in Q4 2025, which was up 189.21% from $382.5 million recorded in Q3 2025.
  • In the past 5 years, IDEAYA Biosciences' Non-Current Assets ranged from a high of $442.6 million in Q4 2025 and a low of $17.5 million during Q3 2022
  • Over the past 5 years, IDEAYA Biosciences' median Non-Current Assets value was $123.5 million (recorded in 2021), while the average stood at $178.7 million.
  • In the last 5 years, IDEAYA Biosciences' Non-Current Assets surged by 124883.07% in 2021 and then tumbled by 8661.11% in 2022.
  • IDEAYA Biosciences' Non-Current Assets (Quarter) stood at $130.4 million in 2021, then plummeted by 86.56% to $17.5 million in 2022, then skyrocketed by 566.19% to $116.7 million in 2023, then skyrocketed by 272.27% to $434.4 million in 2024, then rose by 1.89% to $442.6 million in 2025.
  • Its Non-Current Assets was $442.6 million in Q4 2025, compared to $382.5 million in Q3 2025 and $355.7 million in Q2 2025.